• Sheraton New York Times Square Hotel (map)
  • 811 7th Avenue
  • New York, NY, 10019
  • United States

Session Chairs:  Cornelis J.M. Melief, Leiden University Medical Center and ISA Pharmaceuticals BV, Leiden, The Netherlands, and Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO

8:50 a.m.  Cornelis J.M. Melief, Leiden University Medical Center and ISA Pharmaceuticals BV, Leiden, The Netherlands
Selection of cancer antigens and conditions for success of immunotherapy of cancer involving vaccination

9:25 a.m.  Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO
Therapeutically active neoantigen-specific cancer vaccines

10:00 a.m. Refreshment Break

10:30 a.m.  Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA
A personalized neoantigen vaccine in patients with high risk melanoma*

10:45 a.m.  Ugur Sahin, TRON, Mainz, Germany
Individualizing cancer medicine by engineered RNA immunotherapies

11:15 a.m.  Sara Mangsbo, Uppsala University, Uppsala, Sweden
T cell responses to peptide-epitopes of choice can be boosted by immune complexes of circulating anti-tetanus toxoid antibodies*

11:30 a.m.  Ton Schumacher, The Netherlands Cancer Institute, Amsterdam, The Netherlands
T cell recognition and tumor resistance in human cancer

* Proffered presentation